AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06024603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Drug Sensitivity Test (DST)
Description: Refractory cancer tissue will be collected from participants and subjected to single-drug testing while DNA is simultaneously sent for targeted gene sequencing. Drug sensitivity scores from the tests will become available for a final list of therapeutic options ranked best in order of preference together with suggested doses and schedules.
Study NCT06242301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The collective person-centered dialogue intervention
Description: * Educate and train the interdisciplinary team and staff.~* Upon hospitalisation, the interdisciplinary team introduces an interactive dialogue tool to patients and their relatives. The tool is designed to facilitate a person-centered dialogue and assess the patients' needs, motivations, and challenges regarding eating and physical activity during hospitalization and in everyday settings.~* Following the needs assessment, the interdisciplinary team will introduce and initiate a personalised action plan based on a predefined template that includes suggestions for actions related to the needs assessment.~* Collaboratively, the interdisciplinary team, patients, and relatives evaluate and adjust the action plan, discussing relevant actions and potential community support for maintaining daily activities.~* Before discharge, discussions are guided by predefined questions. Patients receive a contact number for follow-up and information on oral nutritional supplementation prescriptions.
Study NCT05067387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study NCT05067387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Oral THC (20 mg)
Study NCT05067387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Oral CBD (20 mg)
Study NCT05067387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC + CBD
Description: Oral THC (20 mg) + CBD (20 mg)
Study NCT04721210 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: The investigated method is called transcranial magnetic The impact on the SMA will be made using a special inductor of the double conical coil type. Navigation will be carried out through the use of the international system 10-20%. The threshold of motor response will be determined by stimulating the motor area of the legs with the intensity of stimulation necessary to trigger a motor response with an amplitude of more than 50 mv.
Study NCT04721210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: The investigated method is called transcranial magnetic The impact on the SMA will be made using a special inductor of the double conical coil type. Navigation will be carried out through the use of the international system 10-20%. The threshold of motor response will be determined by stimulating the motor area of the legs with the intensity of stimulation necessary to trigger a motor response with an amplitude of more than 50 mv.
Study NCT05919888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Applied to skin incision.
Study NCT05919888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SURGX Wound Gel
Description: Applied to skin incision.
Study NCT04903535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alonefire SV003 10W 365nm UV Flashlight
Description: Investigator will use a Nitric Oxide Analyzer while attached to a small suction port on the subject's ear lobe to be tested for Nitric Oxide. After getting the baseline assay, the investigator will shine a low-intensity UV Flashlight (Alonefire SV003 10W 365nm UV Flashlight) at the ear lobe for 10 seconds, repeated three times at 20 second intervals, to determine if there is photobleaching. Then the assay will then be performed on the opposite ear lobe. Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). The subject and the investigator will wear UV goggles during the experiment.
Study NCT04502563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring and predictive analytics
Description: Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
Study NCT04502563 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
Study NCT03873922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet intervention
Description: Ketogenic, really low carbohydrate containing (15-20 g/day), meals will be offered to the participants.
Study NCT06358768 — intervention group
Intervention type: OTHER
Intervention: teamwork job improvement overall
Description: increase of teamwork capacities and skills improvement
Study NCT06122506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cerclage
Description: Classic or robot-assisted laparoscopic cerclage in non-pregnant or early pregnant women.
Study NCT06122506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal cerclage
Description: Transvaginal cerclage in pregnant women.
Study NCT05280353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glubran 2
Description: Application of Glubran 2 sealant (liquid) in axillary hollow
Study NCT05870488 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Use of iFuse TORQ
Description: Use of iFuse TORQ for the treatment of SI Joint dysfunction
Study NCT05717400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by vein (IV)
Study NCT05717400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by vein (IV)
Study NCT05717400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Given by PO
Study NCT05717400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Given by PO
Study NCT05717400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Given by PO
Study NCT05717400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Given by PO
Study NCT06009094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005
Description: VC005 group with Local topical application
Study NCT06009094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VC005 Placebo
Description: VC005 Placebo group with Local topical application
Study NCT06587490 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy
Description: Stereotactic ablative radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.
Study NCT06719804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Oral administration is given solely for the epilepsy seizure event. Dosage: 20mg per dose; The patient's blood pressure and heart rate are monitored after the seizure; if the SBP is above 90 mmHg and the heart rate is above 60 beats per minute, then patients are instructed to take propranolol within 1 hour of a seizure . If the seizure frequency is excessively high, the interval between doses should be no less than 6 hours and the medication should not be administered more than 3 times a day.
Study NCT06727435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-sedation strategy
Description: Patients eligible for this study will undergo non-sedation strategy, which continuous analgesia without sedation is performed with remifentanil. The remifentanil will be titrated (from 0.1µg/kg/min to 0.2ug/kg/min) every 10-15 minutes to achieve the goal for sedation (RASS score maintaining -2 to + 1). The patients in the non-sedation trial do not receive any sedatives but could receive bolus doses (2.5 or 5mg) of morphine for analgesia.
Study NCT06725316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-7-8 breathing exercises
Description: Steps of doing 4-7-8 breathing exercise; firstly, the breath taken is exhaled completely through the mouth as if whistling. Then the lips are closed and inhaled quietly through the nose (4 seconds). The breath is held for seven seconds. At the last stage, the lips are tightened and exhaled through the mouth for 8 seconds. Then normal breathing is done for one minute. Breathing is repeated four times every hour.
Study NCT06725914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: kangaroo care
Description: Transport practice with paternal kangaroo care in preterm infants
Study NCT06726421 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: The preferred treatment plan is SBRT with a fraction dose ≥7 Gy. The prescription dose should ensure a BED of no less than 115. Radiotherapy is usually delivered daily, every other day, or other interval decided by treating radiation oncologist.
Study NCT06726421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib
Description: Standard systemic therapy are targeted agents or their combination with immunotherapy recommended by guidelines. This may include axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, etc.
Study NCT06726421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib
Description: Standard systemic therapy are targeted agents or their combination with immunotherapy recommended by guidelines. This may include axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, etc.
Study NCT06725589 — intervention group
Intervention type: OTHER
Intervention: metabolic disease
Description: metabolic disease
Study NCT06727344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Exercise with restriction of blood flow supply
Study NCT06727344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brace
Description: Knee brace to restrict range of motion
Study NCT06727344 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brace
Description: Knee brace to restrict range of motion
Study NCT06725758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-212
Description: ODM-212 5mg and/or 40mg tablets
Study NCT06725745 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey containing a primary survey regarding basic demographic features, medical treatment and organization of care and two validated questionnaires.
Study NCT06726005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional appliance twin block
Description: 3D facial scans will be taken (prior to the treatment, at rest and at mandible moved forward to class I dental relation (Fraenkel manouver)) and at the end of treatment, one year later.
Study NCT06725056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DS-MCE and EGD examinations
Description: sequentially performing DS-MCE and EGD examinations on AUGIB patients with stable hemodynamics
Study NCT06725511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out framing
Description: Outreach notifies those eligible that they are enrolled in the program and invites them to start participating.
Study NCT06725511 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opt-in framing
Description: Eligible participants are invited to enroll
Study NCT06726083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention
Description: Weekly virtual live group sessions led by a trained study team member will be held twice weekly for 1 hour/week over 12 weeks using a HIPAA compliant online platform. The first class of each week will include the teaching kitchen cooking demonstration (\~30 min) and the remainder of the class will focus on dietary education. The second class each week will provide an opportunity for group discussion to have Veterans share to their peers about how they used the weekly produce
Study NCT06726083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contact Control
Description: Weekly virtual live group health education sessions led by staff will be held for two hours/week over 12 weeks. We will enroll up to 15 participants into each virtual class cohort and run multiple different group sessions for a total sample size of 90 participants. The content follows the LIFE study structured successful aging health education curriculum80,81 which was designed to increase self-efficacy and empower older Veterans to take control of their own healthcare. Topics focus on a broad range of healthy aging, such as importance of sleep, safe travel, goal setting, self-care, and common comorbidities
Study NCT06725641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test preparation：Methylcholine chloroacetate for inhalation
Description: Cholinergic agonists
Study NCT06725641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference preparation：Methylcholine chloroacetate for inhalation（Provocholine）
Description: Cholinergic agonists
Study NCT05892328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watermelon Flesh Dose 1
Description: 1 cup watermelon flesh, \~152g, 7 days/week over a 4-week period
Study NCT05892328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watermelon Flesh Dose 2
Description: 2 cups watermelon flesh, \~304 g, 7 days/week over a 4-week period
Study NCT05892328 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 304g italian ice, 0 g watermelon, 7 days/week over a 4-week period
Study NCT04718792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom fruiting bodies, manufactured under current Good Manufacturing Practices (cGMP)
Study NCT05732610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MGC Health COVID-19 & Flu A+B Home Multi Test
Description: self-collected direct anterior nares swab samples
Study NCT05732610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)
Description: adult lay user collected anterior nares swab sample
Study NCT06358768 — intervention group
Intervention type: OTHER
Intervention: teamwork job improvement in actor scenario vs mannequin scenario
Description: increase of teamwork capacities and skills improvement. Comparison within different roles and different scenario learning
Study NCT06263933 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Insight Scale
Description: Before the patient was in DIPEM or control group and after the patient is involved in DIPEM or control group
Study NCT06263933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insight Scale
Description: Before the patient was in DIPEM or control group and after the patient is involved in DIPEM or control group
Study NCT04661917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2327949
Description: 60 mg of BAY2327949 (2 tablets of 30 mg, orally) once daily for 28 days.
Study NCT04661917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo orally once daily for 28 days.
Study NCT05032651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: novel artificial intelligence assisted platform
Description: Use of a novel artificial intelligence assisted platform
Study NCT04175938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearing of contact lens
Description: All subjects will wear a contact lens for three hours. The effect of the lens on the eye (epithelial swelling) will be measured at intervals after the lens is removed.
Study NCT04175938 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wearing of contact lens
Description: All subjects will wear a contact lens for three hours. The effect of the lens on the eye (epithelial swelling) will be measured at intervals after the lens is removed.
Study NCT05798624 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound between 6+0 and 6+7 weeks of pregnancy - With Isthmocele
Description: Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior)~Size of isthmocele:~* Depth of isthmocele~* Width of isthmocele~* Circumference of isthmocele~Distance between isthmocele and outer cervical os (measured with the trace line) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac Measurements of the isthmocele size / circumference / distance between isthmocele / CS and outer cervical os
Study NCT05798624 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound between 6+0 and 6+7 weeks of pregnancy - Without Isthmocele
Description: Location of implantation of the GS amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac
Study NCT05371912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trans Cranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neurostimulation technique that alters cortical excitability by repeated induction of electromagnetic activity. FDA approved for depression, rTMS is a promising tool in the field of neuropsychiatry with an excellent safety profile.
Study NCT05533424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quadratus lumborum
Description: the patient will be positioned supine with lateral tilt , and the transducer was placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles were clearly identified. The external oblique muscle was followed posterolaterally until its posterior border was visualized . The probe was tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip was placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle was proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine was applied
Study NCT05533424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane
Description: the probe will located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall were identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique was used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine was injected. The same technique will be performed on the other side
Study NCT04673578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)
Study NCT04673578 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose
Study NCT06267222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRANSCRANIAL DIRECT CURRENT STIMULATION + exercises
Description: Participants with SCA will receive trans-spinal tDCS and exercises. There will be no control group or sham stimulation. All participants will receive real tDCS stimulation
Study NCT05476016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared (NIR)
Description: NIR spectral assessment of glycated nail keratin vs HbA1c
Study NCT06323252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MastihaOil
Description: 1 soft gel capsule of Mastiha oil every day for 3 months
Study NCT06323252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutritional counsel
Description: nutritional counsel
Study NCT05830630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine methylene blue
Description: Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively
Study NCT05830630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine saline
Description: Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively